Abstract
Mutation of a single amino acid in the ligand-binding domain (LBD) of the human androgen receptor (hAR) can induce functional abnormalities in androgen binding, stabilization of active conformation, or interaction with coactivators. The Gly708Ala and Gly708Val substitutions are associated with partial and complete androgen insensitivity syndromes, respectively. In this work, we introduced Ala, Val, and aromatic Phe mutations at position 708 on helix H3 of the hAR-LBD and tested the functional and structural consequences on hAR activity in the presence of steroidal or nonsteroidal agonists and antagonists. The residues involved in the specific recognition of these androgen ligands were identified and analyzed in the light of in vitro biological experiments and the 3D hAR-LBD structure. Our study demonstrated that the Gly708Ala mutation influenced the agonist versus antagonist activity of the ligands and confirmed the crucial role of this residue within the ligand-binding pocket (LBP) in the modulation of androgen agonists. The Gly708Ala mutation transformed the antiandrogen cyproterone acetate (CPA), a partial agonist, into a pure antiandrogen, and the pure nonsteroidal antiandrogen hydroxyflutamide in a partial agonist. From the docking studies, we suggest that CPA acts on AR through the novel mechanism called “passive antagonism”.
Footnotes
-
This work was supported by the Institut National de la Santé et de la Recherche Médicale, and grant 5205 from the Association pour la Recherche sur le Cancer.
- Abbreviations:
- AR
- androgen receptor
- LBD
- ligand binding domain
- hAR
- human androgen receptor
- AIS
- androgen insensitivity syndrome
- DHT
- dihydrotestosterone
- CPA
- cyproterone acetate
- hMR
- human mineralocorticoid receptor
- LBP
- ligand binding pocket
- R1881
- methyltrienolone
- MGA
- megestrol acetate
- CMA
- chlormadinone acetate
- wt
- wild type
- MMTV
- murine mammary tumor virus
- CMV
- cytomegalovirus
- DCC
- dextran-coated charcoal
- FCS
- fetal calf serum
- CDTA
- trans-1,2-diaminocyclohexane-N,N,N′,N′-tetraacetic acid
- GA1
- 11β-vinyl-3-oxo-19-nor-17α-pregna-4,9-diene-21,17-carbolactone
- Received October 18, 2002.
- Accepted December 17, 2002.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|